Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice

Psychoneuroendocrinology

Volumn 38, Issue 10, 2013, Pages 1985-1993

  Neumann, Inga D ^a   Maloumby, Rodrigue ^a   Beiderbeck, Daniela I ^a   Lukas, Michael ^a   Landgraf, Rainer ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Amygdala; Blood brain barrier; Hippocampus; Intraperitonal; Nasal; Oxytocin

Indexed keywords

OXYTOCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG UPTAKE; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

AMYGDALA; BLOOD-BRAIN BARRIER; HIPPOCAMPUS; INTRAPERITONAL; NASAL; OXYTOCIN;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVENOUS; AMYGDALA; ANIMALS; BRAIN; HIPPOCAMPUS; MALE; MICE; MICE, INBRED C57BL; MICRODIALYSIS; OXYTOCIN; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 84883866922     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2013.03.003     Document Type: Article

References (54)

1. Alcalay R.N., Giladi E., Pick C.G., Gozes I. Intranasal administration of nap, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci. Lett. 2004, 361:128-131.
2. Bartz J.A., Zaki J., Bolger N., Ochsner K.N. Social effects of oxytocin in humans: context and person matter. Trends Cogn. Sci. 2011, 15:301-309.
3. Benedict C., Hallschmid M., Schmitz K., Schultes B., Ratter F., Fehm H.L., Born J., Kern W. Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 2006, 32:239-243.
4. Benveniste H. Brain microdialysis. J. Neurochem. 1989, 52:1667-1679.
5. Born J., Lange T., Kern W., McGregor G.P., Bickel U., Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 2002, 5:514-516.
6. Bowen M.T., Carson D.S., Spiro A., Arnold J.C., McGregor I.S. Adolescent oxytocin exposure causes persistent reductions in anxiety and alcohol consumption and enhances sociability in rats. PLoS ONE 2012, 6:e27237.
7. Buijs R.M., Velis D.N., Swaab D.F. Extrahypothalamic vasopressin and oxytocin innervation of fetal and adult rat brain. Prog. Brain Res. 1980, 53:159-167.
8. Chen X.Q., Fawcett J.R., Rahman Y.E., Ala T.A., Frey I.W. Delivery of nerve growth factor to the brain via the olfactory pathway. J. Alzheimers Dis. 1998, 1:35-44.
9. Cushing B.S., Carter C.S. Peripheral pulses of oxytocin increase partner preferences in female, but not male, prairie voles. Horm. Behav. 2000, 37:49-56.
10. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 2010, 99:1654-1673.
11. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal drug targeting of hypocretin-1 (orexin-a) to the central nervous system. J. Pharm. Sci. 2009, 98:2501-2515.
12. Feifel D., Macdonald K., Nguyen A., Cobb P., Warlan H., Galangue B., Minassian A., Becker O., Cooper J., Perry W., Lefebvre M., Gonzales J., Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 2010, 68:678-680.
13. Frey W.H. Bypassing the blood-brain barrier to delivery therapeutic agents to the brain and spinal cord. Drug Deliv. Technol. 2002, 5:46-49.
14. Gamer M., Zurowski B., Buechel C. Different amygdala subregions mediate valence-related and attentional effects of oxytocin in humans. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:9400-9405.
15. Gossen A., Hahn A., Westphal L., Prinz S., Schultz R.T., Gründer G., Spreckelmeyer K.N. Oxytocin plasma concentrations after single intranasal oxytocin administration - a study in healthy men. Neuropeptides 2012, 46:211-215.
16. Gozes I., Bardea A., Reshef A., Zamostiano R., Zhukovsky S., Rubinraut S., Fridkin M., Brenneman D.E. Neuroprotective strategy for alzheimer disease: Intranasal administration of a fatty neuropeptide. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:427-432.
17. Grippo A.J., Trahanas D.M., Zimmerman Ii R.R., Porges S.W., Carter C.S. Oxytocin protects against negative behavioral and autonomic consequences of long-term social isolation. Psychoneuroendocrinology 2009, 34:1542-1553.
18. Guastella A.J., Einfeld S.L., Gray K.M., Rinehart N.J., Tonge B.J., Lambert T.J., Hickie I.B. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol. Psychiatry 2010, 67:692-694.
19. Hanson L., Frey W. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008, 9. 10.1186/1471-2202-1189-S1183-S1185.
20. Hollander E., Bartz J., Chaplin W., Phillips A., Sumner J., Soorya L., Anagnostou E., Wasserman S. Oxytocin increases retention of social cognition in autism. Biol. Psychiatry 2007, 61:498-503.
21. Hollander E., Novotny S., Hanratty M., Yaffe R., DeCaria C.M., Aronowitz B.R., Mosovich S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and asperger's disorders. Neuropsychopharmacology 2002, 28:193-198.
22. Horvat-Gordon M., Granger D.A., Schwartz E.B., Nelson V.J., Kivlighan K.T. Oxytocin is not a valid biomarker when measured in saliva by immunoassay. Physiol. Behav. 2005, 84:445-448.
23. Ionescu I.A., Dine J., Yen Y.-C., Buell D.R., Herrmann L., Holsboer F., Eder M., Landgraf R., Schmidt U. Intranasally administered neuropeptide s (nps) exerts anxiolytic effects following internalization into nps receptor-expressing neurons. Neuropsychopharmacology 2012, 37:1323-1337.
24. Kawarabayashi T., Kuriyama K., Nakashima T., Kiyohara T., Sugimori H. Oxytocin modulates oxytocin neurons in the paraventricular nuclei of female rats throughout pregnancy and parturition. Am. J. Obstet. Gynecol. 1993, 168:969-974.
25. Kirsch P., Esslinger C., Chen Q., Mier D., Lis S., Siddhanti S., Gruppe H., Mattay V.S., Gallhofer B., Meyer-Lindenberg A. Oxytocin modulates neural circuitry for social cognition and fear in humans. J. Neurosci. 2005, 25:11489-11493.
26. Knobloch H.S., Charlet A., Hoffmann L.C., Eliava M., Khrulev S., Cetin A.H., Osten P., Schwarz M.K., Seeburg P.H., Stoop R., Grinevich V. Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron 2012, 73:553-566.
27. Labuschagne I., Phan K.L., Wood A., Angstadt M., Chua P., Heinrichs M., Stout J.C., Nathan P.J. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology 2010, 35:2403-2413.
28. Landgraf R. Plasma oxytocin concentrations in man after different routes of administration of synthetic oxytocin. Exp. Clin. Endocrinol. 1985, 85:245-248.
29. Landgraf R., Neumann I.D. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front. Neuroendocrinol. 2004, 25:150-176.
30. Lischke A., Gamer M., Berger C., Grossmann A., Hauenstein K., Heinrichs M., Herpertz S.C., Domes G. Oxytocin increases amygdala reactivity to threatening scenes in females. Psychoneuroendocrinology 2012, 37:1431-1438.
31. Lukas M., Neumann I.D. Nasal application of neuropeptide s reduces anxiety and prolongs memory in rats: social versus non-social effects. Neuropharmacology 2012, 62:398-405.
32. Marks D.R., Tucker K., Cavallin M.A., Mast T.G., Fadool D.A. Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J. Neurosci. 2009, 29:6734-6751.
33. Matsuoka Y., Gray A.J., Hirata-Fukae C., Minami S.S., Waterhouse E.G., Mattson M.P., LaFerla F.M., Gozes I., Aisen P.S. Intranasal nap administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of alzheimer's disease at early pathological stage. J. Mol. Neurosci. 2007, 31:165-170.
34. Mens W.B.J., Witter A., Van Wimersma Greidanus T.B. Penetration of neurohypophyseal hormones from plasma into cerebrospinal fluid (csf): half-times of disappearance of these neuropeptides from csf. Brain Res. 1983, 262:143-149.
35. Meyer-Lindenberg A., Domes G., Kirsch P., Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat. Rev. Neurosci. 2011, 12:524-538.
36. Meyer-Lindenberg A., Tost H. Neural mechanisms of social risk for psychiatric disorders. Nat. Neurosci. 2012, 15:663-668.
37. Moos F., Freund-Mercier M.J., Guerné Y., Guerné J.M., Stoeckel M.E., Richard P. Release of oxytocin and vasopressin by magnocellular nuclei in vitro: specific facilitatory effect of oxytocin on its own release. J. Endocrinol. 1984, 102. 63-NP.
38. Neumann I., Koehler E., Landgraf R., Summy-Long J. An oxytocin receptor antagonist infused into the supraoptic nucleus attenuates intranuclear and peripheral release of oxytocin during suckling in conscious rats. Endocrinology 1994, 134:141-148.
39. Neumann I.D., Landgraf R. Balance of brain oxytocin and vasopressin: Implications for anxiety, depression, and social behaviors. Trends Neurosci. 2012, 35:649-659.
40. Neumann I.D., Wigger A., Liebsch G., Holsboer F., Landgraf R. Increased basal activity of the hypothalamo-pituitary-adrenal axis during pregnancy in rats bred for high anxiety-related behaviour. Psychoneuroendocrinology 1998, 23:449-463.
41. Nonaka N., Farr S.A., Kageyama H., Shioda S., Banks W.A. Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins. J. Pharmacol. Exp. Ther. 2008, 325:513-519.
42. Nyuyki K.D., Maloumby R., Reber S.O., Neumann I.D. Comparison of corticosterone responses to acute stressors: chronic jugular vein versus trunk blood samples in mice. Stress 2012, 15:618-626.
43. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 1997, Academic Press, San Diego, CA.
44. Paxinos G., Watson C. The brain in stereotaxic coordinates 1998, Academic Press, San Diego, CA.
45. Rat D., Schmitt U., Tippmann F., Dewachter I., Theunis C., Wieczerzak E., Postina R., van Leuven F., Fahrenholz F., Kojro E. Neuropeptide pituitary adenylate cyclase-activating polypeptide (pacap) slows down alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 2011, [EPup]. 10.1096/fj.10-180133.
46. Reger M.A., Watson G.S., Green P.S., Wilkinson C.W., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Breitner J.C., DeGroodt W., Mehta P., Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early ad. Neurology 2008, 70:440-448.
47. Shamay-Tsoory S.G., Fischer M., Dvash J., Harari H., Perach-Bloom N., Levkovitz Y. Intranasal administration of oxytocin increases envy and schadenfreude (gloating). Biol. Psychiatry 2009, 66:864-870.
48. Slattery D.A., Neumann I.D. Chronic icv oxytocin attenuates the pathological high anxiety state of selectively bred wistar rats. Neuropharmacology 2010, 58:56-61.
49. Striepens N., Kendrick K.M., Maier W., Hurlemann R. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front. Neuroendocrinol. 2011, 32:426-450.
50. Thompson R., Gupta S., Miller K., Mills S., Orr S. The effects of vasopressin on human facial responses related to social communication. Psychoneuroendocrinology 2004, 29:35-48.
51. Wegener G., Finger B.C., Elfving B., Keller K., Liebenberg N., Fischer C.W., Singewald N., Slattery D.A., Neumann I.D., Mathé A.A. Neuropeptide s alters anxiety, but not depression-like behaviour in flinders sensitive line rats: a genetic animal model of depression. Int. J. Neuropsychopharmacol. FirstView 2011, 1-13.
52. Weisman O., Zagoory-Sharon O., Feldman R. Intranasal oxytocin administration is reflected in human saliva. Psychoneuroendocrinology 2012, 37:1582-1586.
53. Xu Y.L., Reinscheid R.K., Huitron-Resendiz S., Clark S.D., Wang Z., Lin S.H., Brucher F.A., Zeng J., Ly N.K., Henriksen S.J., de Lecea L., Civelli O. Neuropeptide s: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 2004, 43:487-497.
54. Zink C.F., Stein J.L., Kempf L., Hakimi S., Meyer-Lindenberg A. Vasopressin modulates medial prefrontal cortex-amygdala circuitry during emotion processing in humans. J. Neurosci. 2010, 30:7017-7022.